Nexalin Technology, Inc. (NXL) Latest Company News

Oct 8, 2026, 12:30 UTC
Nexalin Technology, Inc. said it regained compliance with NASDAQ, INC.’s minimum bid price requirement and that a NASDAQ, INC. Hearings Panel granted its request for continued listing.
Source:
- globenewswire.com
Oct 1, 2026, 21:04 UTC
Nexalin Technology signed an exclusive distribution agreement appointing INOVANEXA MEDICAL TECHNOLOGIES S.A. to distribute its Nexalin Sync neurostimulation device in Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela.
Sep 2, 2026, 20:54 UTC
Carolyn Shelton departed as Senior Vice President of Quality, Regulatory, and Clinical Affairs at Nexalin Technology, Inc., effective August 28, 2026, with severance including one month of base salary, a $20,000 bonus for 2026, accelerated stock option vesting, and health insurance subsidy through September 30, 2026.
Aug 20, 2026, 00:00 UTC
Nexalin Technology, Inc. signed a securities purchase agreement on August 19, 2026 to issue and sell 2,419,355 shares of common stock at $0.31 per share in a registered direct offering, with concurrent warrants to purchase up to 1,209,677 shares at $0.50 per share, expecting gross proceeds of approximately $750,000.
Aug 20, 2026, 00:00 UTC
Nexalin Technology, Inc. signed an Any Market Purchase Agreement with Alumni Capital LP on August 19, 2026, granting the company the right to sell up to $15 million of common stock in a series of purchases, with the agreement expiring December 31, 2027.
Aug 17, 2026, 00:00 UTC
Nexalin Technology, Inc. received a notice from Nasdaq on 2026-08-14 for non-compliance with the Stockholders' Equity Requirement (Rule 5550(b)(1)) and requested a hearing before the Nasdaq Hearing Panel to present its remediation plan.
Jun 29, 2026, 18:45 UTC
The US Patent and Trademark Office issued US Patent 12,629,519 to Nexalin Technology Inc for its non-invasive deep-brain neurostimulation method targeting insomnia, anxiety, and depression.
Source:
- sleepreviewmag.com
Jun 10, 2026, 13:15 UTC
Nexalin Technology reported clinical trial results in Brazil to support the launch of its DIFS 15 mA 77.5 Hz treatment platform.
Source:
- globenewswire.com

NXL

Nexalin Technology, Inc. said it regained compliance with NASDAQ, INC.’s minimum bid price requirement and that a NASDAQ, INC. Hearings Panel granted its request for continued listing.

Nexalin Technology signed an exclusive distribution agreement appointing INOVANEXA MEDICAL TECHNOLOGIES S.A. to distribute its Nexalin Sync neurostimulation device in Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela.

Nexalin Technology, Inc. signed an Any Market Purchase Agreement with Alumni Capital LP on August 19, 2026, granting the company the right to sell up to $15 million of common stock in a series of purchases, with the agreement expiring December 31, 2027.

Nexalin Technology, Inc. received a notice from Nasdaq on 2026-08-14 for non-compliance with the Stockholders' Equity Requirement (Rule 5550(b)(1)) and requested a hearing before the Nasdaq Hearing Panel to present its remediation plan.

The US Patent and Trademark Office issued US Patent 12,629,519 to Nexalin Technology Inc for its non-invasive deep-brain neurostimulation method targeting insomnia, anxiety, and depression.

Nexalin Technology reported clinical trial results in Brazil to support the launch of its DIFS 15 mA 77.5 Hz treatment platform.